AC699
- Generic Name
- AC699
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05654532
- Locations
- 🇺🇸
Site 02, Sarasota, Florida, United States
🇺🇸Site 03, Houston, Texas, United States
🇺🇸Site 01, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath